Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454350 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
A Phase 4 study of Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00454350 is a Phase 4 study of Secondary Hyperparathyroidism that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 12 participants, below the 63-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00454350, a Phase 4 study of Secondary Hyperparathyroidism, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
Conditions Studied
Interventions
- DRUG Hectorol (doxercalciferol injection)
- DRUG Zemplar (Paricalcitol injection)
Study Locations (1)
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454350
The ClinicalTrials.gov registry entry for NCT00454350 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (81% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Hectorol (doxercalciferol injection) is the first listed.
NCT00454350 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00454350 about?
NCT00454350 is a clinical study titled "A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis". This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
What is the current status of trial NCT00454350?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2007-02. Estimated completion is 2007-07.
What conditions does trial NCT00454350 study?
This clinical trial studies the following conditions: Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT00454350?
The interventions under investigation include: Hectorol (doxercalciferol injection) (DRUG), Zemplar (Paricalcitol injection) (DRUG).
Who is sponsoring clinical trial NCT00454350?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00454350 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
-
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
COMPLETED · Phase 4
-
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
COMPLETED · Phase 4
-
Precision Medicine Approaches to Renal Osteodystrophy
RECRUITING
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.